ClinicalTrials.Veeva

Menu

Cardiac Amyloidosis in HFpEF Tunisian Patients (Amy-Card)

U

University Tunis El Manar

Status

Enrolling

Conditions

Cardiac Amyloidosis
Heart Failure With Preserved Ejection Fraction
Diagnosis
Prevalence
CMR
Echocardiography
Bone Scintigraphy

Study type

Observational

Funder types

Other

Identifiers

NCT06201832
13-2023

Details and patient eligibility

About

Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations.

Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis.

In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.

Enrollment

87 estimated patients

Sex

All

Ages

60 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • HFpEF during the previous year
  • IVS thickness of 12mm or greater

Exclusion criteria

  • age under 60 years
  • Acute coronary syndrome complicated by HFpEF
  • Congenital heart disease

Trial contacts and locations

1

Loading...

Central trial contact

Lilia Zakhama, Prof

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems